Zheng Wang

Dr. Zheng Wang

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2022 in Journal of Psychiatric Research
Verified
Journal Article
Closed access
ZFZhe Fang
Zhe Fang
QMQingli Mu
Qingli Mu
CWCongchong Wu
Congchong Wu
LJLili Jia
Lili Jia
ZWZheng Wang
Zheng Wang
SLShaojia Lu
Shaojia Lu

14 February 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
ZWZheng Wang
Zheng Wang
DZDanhua Zhang
Danhua Zhang
YDYanli Du
Yanli Du
YWYin Wang
Yin Wang
THTingting Huang
Tingting Huang
SHShaohua Hu
Shaohua Hu
Effective pharmacotherapy of bipolar depression with mixed features defined by DSM-5 remains unclear in clinical treatment guidelines. Quetiapine (QTP) and valproate have potential treatment utility but are often inadequate as monotherapy. Meanwhile, the efficacy of combination therapies of QTP plus valproate or lithium have yet to be verified. Hence, we conducted a randomized controlled pilot study to evaluate the efficacy of QTP monotherapy in patients with bipolar depression with mixed features defined by DSM-5 and compared the combination therapy of QTP plus valproate (QTP + V) versus QTP plus lithium (QTP + L) for those patients who responded insufficiently to QTP monotherapy. Data was analyzed according to the intent-to-treat population. Generalized linear mixed model was performed by using “nlme” package in R software. A total 56 patients were enrolled, among which, 35 patients responded to QTP alone, and 11 and 10 patients were randomly assigned to QTP + V and QTP + L group, respectively. Nearly 60% enrolled patients responded to QTP monotherapy at the first two weeks treatment. No statistically significant difference in efficacy between QTP + V and QTP + L was observed. In conclusion, QTP monotherapy appeared to be efficacious in patients with bipolar depression with mixed features, and for those who responded insufficiently to QTP, combining with either valproate or lithium appeared to have positive effects.

26 June 2020 in Medicine
Verified
Journal Article
Open access
YDYanli Du
Yanli Du
JJJiajun Jiang
Jiajun Jiang
CNChee H. Ng
Chee H. Ng
LWLingling Wu
Lingling Wu
PZPeifen Zhang
Peifen Zhang
ZWZheng Wang
Zheng Wang
Rationale: Rapid eye movement sleep behavior disorder (RBD) is a kind of sleep disturbance characterized by a loss of normal paralysis of REM sleep with dream enactment behavior during REM sleep. The pharmacotherapy options for treating RBD are limited and the use of antidepressants remains controversial. Further, the role of vortioxetine in RBD has not been evaluated so far. Patient concerns: A 72-year-old woman presented with recurrent peculiar behaviors such as shouting, punching, kicking or even walking around her bedroom during sleep for over 3 years. Diagnosis: Clinical examinations and polysomnography indicated the diagnosis of RBD. Interventions: The patient received treatment with paroxetine and melatonin for 1 year and then paroxetine was discontinued and vortioxetine was initiated in a daily dose of 10 mg. Outcomes: Treatment with paroxetine and melatonin for one year was ineffective. A trial of vortioxetine 10 mg per day over 3 months resulted in significant clinical improvement. Lessons: To our knowledge, this is the first reported case of effective treatment of RBD with vortioxetine. Well-designed studies with large samples are needed to verify the clinical benefits.

21 October 2025 in Brain Sciences
Verified
Journal Article
Open access
PDF file
ADAo Du
Ao Du
MHManli Huang
Manli Huang
ZWZheng Wang
Zheng Wang
HZHetong Zhou
Hetong Zhou
HDHuilong Duan
Huilong Duan
Yinfei ZhengYinfei Zheng
Yinfei Zheng
Background: Depression and anxiety disorders impact millions globally. In recent years, low-intensity focused ultrasound (LIFU), characterized by its high precision, deep penetration, and non-invasive nature, has garnered significant interest in neuroscience and clinical practice. To enhance understanding of its effects on mood, therapeutic availability in treatment of depression/anxiety disorders, and potential mechanisms, a systematic review of studies investigating the emotional impact of LIFU on depressive/anxious-like animal models, healthy volunteers, and patients with depression or anxiety disorders has been undertaken. Methods: Relevant papers published before 15 July 2025 were searched across four databases: Web of Science, PubMed, Science Direct, and Embase. A total of 28 papers which met the inclusion and exclusion criteria are included in this review. Results: Our findings indicate that LIFU reversed the depressive/anxious-like behaviors in the animal models and showed antidepressant/anti-anxiety effects among the state-of-art clinical studies. For example, immobility time in FST or TST is reduced in depressive animal models, and HRSD/BAI scales are improved in human studies. Key molecules such as BDNF/5-HT are found restored in animal models, and FC between key brain areas related to depression/anxiety is modulated after LIFU treatment. Notably, no brain tissue damage was observed in animal studies, and only mild adverse effects (such as dizziness and vomiting) were noted in a few human studies. Conclusions: The studies using LIFU to treat depression and anxiety remain in the preliminary stage. The mechanisms underlying LIFU’s mood effects—such as activation or inhibition of specific brain regions or neural circuits, anti-inflammatory effects, alterations in functional connectivity, synaptic plasticity, neurotransmitter levels, and BDNF—remain incompletely understood and warrant further investigation. Nevertheless, the LIFU technique holds promise for regulating both cortical and subcortical brain areas implicated in depression/anxiety disorders as a precise neuromodulation tool.

8 April 2026 in Progress in Retinal and Eye Research
Verified
Journal Article
Closed access
XZXuhong Zhang
Xuhong Zhang
XWXiaoyu Wang
Xiaoyu Wang
HZHong Zhu
Hong Zhu
HYHuiwen Yu
Huiwen Yu
LFLin Fu
Lin Fu
JTJianping Tong
Jianping Tong